Human TNFRSF9/4-1BB/CD137 protein (Recombinant) (C-6His) (STJP002895)

SKU:
STJP002895

£72.50 - £273.50
Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human TNFRSF9/4-1BB/CD137-C-6His protein was developed from hek293 cells and has a target region of C-6His. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Immunoreactivity: Measured by its binding ability in a functional ELISA.Immobilized Human TNFRSF9 (Catalog: RP01698) at 2 Mu g/mL (100 Mu L/well) can bind Human TNFSF9 (Catalog: RP00060) with a linear range of 1-4.4 ng/mL.
Gene Symbol: TNFRSF9
Gene ID: 3604
Uniprot ID: TNR9_HUMAN
Immunogen Region: Leu24-Gln186
Immunogen: Recombinant Human Leukemia inhibitory factor/LIF Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Leu24-Gln186) of human TNFRSF9/4-1BB/CD137 (Accession #NP_002300.1) fused with a 6×His tag at the C
Function Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable).
Protein Name Tumor Necrosis Factor Receptor Superfamily Member 9
4-1bb Ligand Receptor
Cdw137
T-Cell Antigen 4-1bb Homolog
T-Cell Antigen Ila
Cd Antigen Cd137
Database Links Reactome: R-HSA-5669034
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Alternative Protein Names Tumor Necrosis Factor Receptor Superfamily Member 9 protein
4-1bb Ligand Receptor protein
Cdw137 protein
T-Cell Antigen 4-1bb Homolog protein
T-Cell Antigen Ila protein
Cd Antigen Cd137 protein
TNFRSF9 protein
CD137 protein
ILA protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance